

# Horizon2020

SC1 – Health, Demographic change and  
Wellbeing - Opportunità per l'area  
“Salute (2016-2017)”



*Caterina Buonocore*

*Horizon 2020*

*Punto di Contatto Nazionale SC1  
Coordinatore dei PCN in APRE*




# AGENDA

- Contesto H2020
- Opportunità in Salute
- Programmazione dei prossimi 3 anni di H2020
- National Contact Points
- Grant Offices/uffici brevetti..ecc

# H2020/ The Three Pillars



# STRUCTURE OF THE PROGRAMME: WHERE HEALTH could fit?





# Struttura del programma H2020

## Excellent Science

- **European Research Council**
  - Frontier research by the best individual teams
- **Future and Emerging Technologies**
  - Collaborative research to open new fields of innovation
- **Marie Skłodowska Curie actions**
  - Opportunities for training and career development
- **Research infrastructures** (including e-infrastructure)
  - Ensuring access to world-class facilities

## Industrial Technologies

- **Leadership in enabling and industrial technologies**
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
  - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
  - Fostering all forms of innovation in all types of SMEs

## Societal Challenges

- **Health, demographic change and wellbeing**
- **Food security, sustainable agriculture, marine and maritime research & the bioeconomy**
- **Secure, clean and efficient energy**
- **Smart, green and integrated transport**
- **Climate action, resource efficiency and raw materials**
- **Inclusive, innovative and reflective societies**
- **Secure societies**

European Institute of Innovation and Technology (EIT)

Spreading Excellence and Widening Participation

Science with and for society

Joint Research Center (JRC)

2° PILLAR

# INDUSTRIAL LEADERSHIP



# Connections to Health in Pillar II

## Industrial Technologies

### ■ Leadership in enabling and industrial technologies


- ICT, nanotechnologies, materials, biotechnology, manufacturing, space

### ■ Access to risk finance

- Leveraging private finance and venture capital for research and innovation

### ■ Innovation in SMEs

- Fostering all forms of innovation in all types of SMEs



# [Health opportunities in ICT]

## ICT-11-2017: Collective Awareness Platforms for Sustainability and Social Innovation

To demonstrating new forms of bottom-up innovation and social collaboration exploiting digital hyper-connectivity and collaborative tools based on open data, open knowledge, open source software and open hardware.

## ICT-15-2016-2017: Big Data PPP: Large Scale Pilot actions in sectors best benefitting from data-driven innovation

Proposal may suggest replicable solutions by using existing or very near-to-market technologies. They may ensure strong industrial domain, possibility to embrace cross-domain activities, to demonstrate data harvesting and analytics added value in industrial ecosystems. Possible industrial sectors **include health**.

## ICT-27-2017: System abilities, SME & benchmarking actions, safety certification (scope c.)

Developing and testing protocols for shared space cooperative and collaborative systems leading to viable safety certification standards. Potential proposals may include **healthcare and elderly or handicapped care applications**.

## ICT-30-2017: Photonics KET 2017 (scope b.)


Biophotonics: **imaging systems for in-depth disease diagnosis**. The objective is the demonstration and validation in real-settings of innovative, easy to operate, compact, and non- or minimally invasive **imaging systems to support diagnosis of age and lyfe-style related diseases**.

→ **Deadline: 25 April 2017**

Proposal Template: 70 pages (single step)

**Idealist – H2020 ICT/FET NCP Network**

<http://www.ideal-ist.eu/>





# Health topics in II PILLAR: NMP

## Excellent Science

- **European Research Council**
  - Frontier research by the best individual teams
- **Future and Emerging Technologies**
  - Collaborative research to open new fields of innovation
- **Marie Skłodowska Curie actions**
  - Opportunities for training and career development
- **Research infrastructures** (including e-infrastructure)
  - Ensuring access to world-class facilities

## Industrial Technologies


- **Leadership in enabling and industrial technologies**
  - ICT, **Nanotechnologies**, materials, biotechnology, manufacturing, space
- **Access to risk finance**
  - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
  - Fostering all forms of innovation in all types of SMEs

## Societal Challenges

- **Health, demographic change and wellbeing**
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

## NMP TeAM – H2020 NMP NCP Network

<http://www.nmpteam.eu/>



## ADVANCED MATERIALS AND NANOTECHNOLOGIES FOR HEALTHCARE (From topics NMBP 12 to 16)

Year	Topic	Topic Title	Instrument	TRL	Deadline
2017	NMBP 12-2017	Development of a reliable methodology for better risk management of engineered <b>biomaterials in Advanced Therapy Medicinal Products and/or Medical Devices</b>	RIA	4, target 6	1 <sup>st</sup> Stage: 27/10/16 2 <sup>nd</sup> Stage: 4/5/17
	NMBP 13-2017	Cross-cutting KETs for <b>diagnostics at the point-of-care</b>	RIA	3/4-5/6	19/1/17
	NMBP 14-2017	Regulatory Science Framework for assessment of risk benefit ratio of <b>Nanomedicines and Biomaterials</b>	IA	5-6	1 <sup>st</sup> Stage: 27/10/16 2 <sup>nd</sup> Stage: 4/5/17
	NMBP 15-2017	Nanotechnologies for <b>imaging cellular transplants and regenerative processes in vivo</b>	RIA	3/4-5/6	1 <sup>st</sup> Stage: 27/10/16 2 <sup>nd</sup> Stage: 4/5/17
	NMBP 16-2017	Mobilising the European <b>nano-biomedical ecosystem</b>	CSA		19/1/17

3° PILLAR


# SOCIETAL CHALLENGES



# HEALTH implications in Societal Challenges

## Societal Challenges

- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society



# Societal Challenge 2- Food...

## Excellent Science

- **European Research Council**
  - Frontier research by the best individual teams
- **Future and Emerging Technologies**
  - Collaborative research to open new fields of innovation
- **Marie Skłodowska Curie actions**
  - Opportunities for training and career development
- **Research infrastructures** (including e-infrastructure)
  - Ensuring access to world-class facilities

## Industrial Technologies


- **Leadership in enabling and industrial technologies**
  - ICT, Nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
  - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
  - Fostering all forms of innovation in all types of SMEs

## Societal Challenges

- **Health, demographic change and wellbeing**
- **Food security, sustainable agriculture, marine and maritime research & the bioeconomy**
- **Secure, clean and efficient energy**
- **Smart, green and integrated transport**
- **Climate action, resource efficiency and raw materials**
- **Inclusive, innovative and reflective societies**
- **Security society**

## BIO Horizon– H2020 SC2/BIO NCP Network

<http://www.ncp-biohorizon.net/start>



## Healthy and safe foods and diets for all

SFS-39-2017: How to tackle the childhood obesity epidemic.

SFS-40-2017: Sweeteners and sweetness enhancers.

## Linking healthy oceans and seas for healthy people

BG-06-2017: Interaction between people, oceans and seas: a strategic approach towards healthcare and well-being

BG-07-2017: Blue green innovation for clean coasts and seas.

BG-08-2017: Innovative sustainable solutions for improving the safety and dietary properties of seafood

# Societal Challenge 7- Security

## Excellent Science

- **European Research Council**
  - Frontier research by the best individual teams
- **Future and Emerging Technologies**
  - Collaborative research to open new fields of innovation
- **Marie Skłodowska Curie actions**
  - Opportunities for training and career development
- **Research infrastructures** (including e-infrastructure)
  - Ensuring access to world-class facilities

## Industrial Technologies


- **Leadership in enabling and industrial technologies**
  - ICT, Nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
  - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
  - Fostering all forms of innovation in all types of SMEs

## Societal Challenges

- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
  - **Security society**

## SEREN3– H2020 SC7NCP Network

<http://www.seren-project.eu/>



### Home

#### ICT Proposers' Day 2016

ICT Proposers' day 2106 in Bratislava, Slovakia on 26 and 27 September is a networking event promoting European ICT Research & Innovation and focusing on the H Programme for 2016-17.

ICT Proposers' Day 2016 is organised on Monday & Tuesday the 26-27 September 2016, as part of Digital Week in Bratislava. This event falls during the Digital Week and Digital Assembly on 29-29 September in Slovakia.

The event will focus on the Horizon 2020 Work Programme 2016-17 in the field of Information & Communication Technologies. It will offer a unique and exceptional oppor

Year	Topic	Topic Title	Instrument	Deadline
2017	CIP 01- 2016-2017	Prevention , detection, response, mitigation of the combination of <b>physical and cyber threats to the critical infrastructure of Europe</b> (including Health Services)	IA	24/08/17

# SC1. HEALTH, DEMOGRAPHIC CHANGE AND WELLBEING





# Work Programme SC1 2016-2017

**Pers. Medicine**

**Broad topics**

**Less prescriptive topic texts**

**Two-year work programme**

**Stronger focus on end users**

**Clinical trials**



## Personalised medicine – towards a definition

*"Personalised medicine refers to a **medical model** using molecular profiling for tailoring the **right therapeutic strategy for the right person at the right time**, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention"*





# SC1 Work Programme 2017

*in brief*

**Call 'Personalised Medicine'**  
**11 topics**


**Including 'Coordination activities'**  
**4 topics**

- ❖ **SME Instrument**  
**2 topics (unchanged from 2016)**
- ❖ **Other Actions**  
**12 items (incl. InnovFin ID and Birth Day Prize)**

**€ 486 million**



# Health in H2020



- Health solutions can imply different phases of research and innovation

# SC1 topics – 2017

Call		Budget	Deadline
SC1-PM-02-2017	New concepts in patient stratification	€40M	4 Oct. 2016 (1 <sup>st</sup> stage)
			11 Apr. 2017 (2 <sup>nd</sup> stage)
SC1-PM-03-2017	Diagnostic characterisation of rare disease	€15M	11 Apr. 2017
SC1-PM-07-2017*	Promoting mental well-being in the young	€20M	4 Oct. 2016 (1 <sup>st</sup> stage)
			11 Apr. 2017 (2 <sup>nd</sup> stage)
SC1-PM-08-2017	New therapies for rare diseases	€60M	4 Oct. 2016 (1 <sup>st</sup> stage)
			11 Apr. 2017 (2 <sup>nd</sup> stage)

\* AMENDED

# SC1 topics – 2017

Call	Budget	Deadline
<b>SC1-PM-11-2017:</b> <b>Clinical research on regenerative medicine</b>	€30M	11 Apr. 2017
<b>SC1-PM-15-2017:</b> <b>Personalised coaching for well-being and care of people as they age</b>	€25M	31 Jan. 2017
<b>SC1-PM-16-2017:</b> <b>In-silico trials for developing and assessing biomedical products</b>	€19M	14 Mar. 2017
<b>SC1-PM-17 – 2017:</b> <b>Personalised computer models and in-silico systems for well-being</b>	€19M	14 Mar. 2017
<b>SC1-PM-19-2017:</b> <b>PPI for uptake of standards for the exchange of digitalised healthcare records</b>	€8.26M	14 Mar. 2017
<b>SC1-PM-20-2017:</b> <b>Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector</b>	€9M	11 Apr. 2017

\* AMENDED

# SC1 topics – 2017 – Other actions

Call	Budget	Deadline
<b>SC1-HCO-08–2017:</b> <b>Actions to bridge the divide in European health research and innovation</b>	€1M	11 Apr. 2017
<b>SMEInst-05-2016-2017:</b> <b>Supporting innovative SMEs in the healthcare biotechnology sector:</b>	€53M (2016)	Multiple cut-off dates in 2016 and 2017
a. Cell technologies in medical applications b. Clinical research for the validation of biomarkers and/or diagnostic medical devices*	€57.3M (2017)**	
<b>InnovFin Infectious Diseases (InnovFin ID) Pilot</b>	€50M (2016) €50M (2017)	From first quarter of 2016
<b>Inducement prize on reducing maternal and new-born morbidity and mortality - the Birth Day Prize</b>	€1M	2017

**SC1 Work Programme** (updated at 25 July 2016)

[http://ec.europa.eu/research/participants/data/ref/h2020/wp/2016\\_2017/main/h2020-wp1617-health\\_en.pdf](http://ec.europa.eu/research/participants/data/ref/h2020/wp/2016_2017/main/h2020-wp1617-health_en.pdf)

# Next SC1 Work Programme 2018-2020

## **VERTICAL themes**

1. Personalised medicine
2. Rare diseases
3. Infectious diseases
4. Non-communicable diseases
5. Paediatrics
6. Public health and prevention including migration
7. Active and healthy ageing

## **HORIZONTAL themes**

8. Big data
9. eHealth, mHealth, ICT
10. Integration of care
11. Environment and health, green solutions and sustainability including climate change

## **CROSS-CUTTING issues**


12. Social Sciences and Humanities, integration, inequalities, migration and ethics
13. Sex and gender differences in medicine
14. Commercialisation within “Health, Demographic Change and Well-being”
15. Encouraging stronger and successful involvement of EU-13

## SC1 and international cooperation

- Reference to specific **multi-lateral initiatives**
- Mutual opening of research programmes with **Third Countries (USA)**
- Funding of Third Countries entities by their **own funding agencies** for participating to Horizon 2020 (Switzerland, Australia)
- Specific actions



# Template for essential information to be provided for proposals including clinical trials / studies / investigations



The use of this template is mandatory for all clinical studies included in a proposal submitted to topics **PM-01, PM-02, PM-06, PM-07, PM-08, PM-09, PM-10, PM-11 and HCO-07**. For these topics, you will have the possibility to upload the completed template as a separate part of your application in the submission system.

Some advices:

- Addition of Annex 2: **Mandatory deliverables** for clinical studies.
- Proposals containing clinical studies submitted to **topics not listed** can use template as an orientation and provide information in concept and approach or in work packages.
- **Risk and contingency plans** have to be addressed in part B3.2 and table 3.2a.
- Clinical centers whose contribution is limited to **subject recruitment or treatment** may have status of full beneficiary: always preferred!
- **Third parties/subcontractors** must be identified in the DoA.
- **3 unique and exclusive (!) personnel categories**: Doctors, Other medical personnel, Technical personnel. (categories for 'nurses' 'study nurses' or 'pharmacists' do not exist!).



# Strategic Initiatives around HEALTH



## Innovative Medicines Initiative 2

[www.imi.europa.eu](http://www.imi.europa.eu)



## European Innovation Partnership on Active and Healthy Ageing

<https://webgate.ec.europa.eu/eipaha>



## Active and Assisted Living 2

[www.aal-europe.eu](http://www.aal-europe.eu)



## European & Developing Countries Clinical Trials Partnership (EDCTP2)

[www.edctp.org](http://www.edctp.org)



innovative  
medicines  
initiative


efpia



enterprise  
europe  
network

26

# IMI 2 budget



EFPIA = **E**uropean **F**ederation of **P**harmaceutical **I**ndustries and **A**ssociation

\* Imaging, Diagnostics, IT for health etc.

# The IMI portfolio



Innovative Medicines Initiative

Corporate contribution


IMI funding

## Partners

<b>AiCuris</b>	<b>Johnson&amp;Johnson</b>
<b>Animal Health</b>	Medimmune
<b>Division of Sanofi</b>	<b>Merck</b>
Astellas	Merck Sharp & Dohme Corp
<b>AstraZeneca</b>	<b>Merial</b>
Basilea	Novartis
<b>Boehringer Ingelheim</b>	<b>Pfizer</b>
Cubist	Rempex
<b>GSK</b>	<b>Sanofi</b>
Janssen	

<b>AstraZeneca</b>	<b>Novartis</b>
<b>Bayer</b>	Pfizer
Janssen	<b>Sanofi</b>
<b>Lundbeck</b>	UCB
Merck	

Abbott	Janssen
<b>AbbVie</b>	<b>Lundbeck</b>
AC IMMUNE	Merck
<b>Amgen</b>	<b>Novartis</b>
Astellas	NOVO NORDISK
<b>AstraZeneca</b>	<b>Orion Corporation</b>
BIOGEN IDEC	Pfizer
<b>Boehringer Ingelheim</b>	<b>Roche</b>
Eisai	Sanofi
<b>Eli Lilly</b>	<b>SERVIER</b>
ESTEVE	UCB
<b>Grunenthal</b>	<b>Vifor</b>
GSK	



efpia

www.apre.it



# Strategic Research Agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes/Metabolic disorders
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines




The right prevention and treatment  
for the right patient at the right time

Strategic Research Agenda for  
Innovative Medicines Initiative 2

**Aligned with  
WHO priorities**

# A Typical IMI Consortium



# Who is eligible for funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises ( $\leq$  €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:

- EU Member States
- Associated Countries

## Other countries:

No funding **unless**

- **participation deemed essential** by IMI for carrying out the action
- **Annual Work Plan / Calls documents**

**New!** At least three legal entities

## IMI 2 – Call 8 includes the following topic:

- ***Ebola and other filoviral haemorrhagic fevers (Ebola+)***  
*programme: future outbreaks*

The indicative budget for the entire period of 2 years is **€70 million**.

### Deadlines

The Call will remain **open for two years**, with the following **cut-off dates**:

- 16 March 2016
- 15 September 2016
- 16 March 2017
- 14 September 2017
- 15 March 2018

## IMI 2 – Call 10 will includes the following topics:

Foreseen launch **Autumn 2016**:

- **Understanding hypoglycaemia**: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
- How **big data** could support better diagnosis and treatment outcomes for **prostate cancer**
- Improving the care of patients suffering from **acute or chronic pain**
- Creation of a pan-European **paediatric clinical trials** network
- **Biomanufacturing 2020**: Development of innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes
- Unlocking the **solute carrier gene-family** for effective new therapies
- Enhanced **patient voice** in medicines lifecycle
- Precision medicines approaches in **autism spectrum disorders**



# Stay in touch

- Visit our website  
[www.imi.europa.eu](http://www.imi.europa.eu)
- Sign up to our newsletter  
[bit.ly/IMInewsletter](http://bit.ly/IMInewsletter)
- Follow us on Twitter  
[@IMI\\_JU](https://twitter.com/IMI_JU)
- Join our LinkedIn group  
[bit.ly/LinkedInIMI](http://bit.ly/LinkedInIMI)
- E-mail us  
[infodesk@imi.europa.eu](mailto:infodesk@imi.europa.eu)





Directorate-General for  
Health & Consumers

DG SANCO

Third **Health Programme** 2014-2020



Il programma si concentra su **quattro obiettivi principali**, il cui scopo è conseguire un forte potenziale di crescita economica grazie al miglior stato di salute:

- 1) **Sviluppare strumenti e meccanismi comuni a livello dell'UE per affrontare la carenza di risorse umane e finanziarie, al fine di contribuire a sistemi sanitari innovativi e sostenibili;**
- 2) **Migliorare l'accesso alle competenze mediche e alle informazioni concernenti patologie specifiche anche su scala transnazionale e sviluppare soluzioni condivise e orientamenti per migliorare la qualità della sanità e della sicurezza dei pazienti.**
- 3) **Individuare, diffondere e promuovere l'adozione di buone pratiche convalidate per prevenire le malattie e promuovere la buona salute.**
- 4) **Sviluppare approcci comuni per proteggere i cittadini dalle minacce sanitarie transfrontaliere.**

[http://ec.europa.eu/health/programme/policy/index\\_en.htm](http://ec.europa.eu/health/programme/policy/index_en.htm)

## CHI NE BENEFICIERÀ E COME

- **Direttamente**: **tutte le amministrazioni pubbliche nazionali ed europee attive** nell'assistenza sanitaria, e gli **organismi privati, le ONG e i gruppi di interesse** che promuovono politiche e sistemi sanitari più adatti alle attuali sfide demografiche e sociali.
- **Indirettamente**: **tutti gli europei**, grazie a una migliore assistenza sanitaria, alla promozione della salute e a misure di prevenzione.

La **partecipazione** è aperta ad una vasta gamma di organizzazioni, tra cui:

- **Gli Istituti di Ricerca , Università e Ospedali**
- **Gli enti pubblici**
- **ONG**
- **Imprese Commerciali**

The EU grant is limited to a **maximum co-funding rate of 60% of eligible costs**. In case of exceptional utility up to 80% can be granted (see Work Plan 2016, Annex VII).

Le dotazioni finanziarie per l'attuazione del programma per il periodo dal 1° gennaio 2014 al 31 dicembre 2020 ammonteranno a **449,4 milioni di EUR**.

# Scaduto

## Deadline: 2<sup>nd</sup> June 2016

TITLE	INDICATIVE AMOUNT, EUR	Ref. in Work Plan 2016	Grants foreseen
Migrants' health: Best practices in care provision for vulnerable migrants and refugees	4.500.000	2.1.1.1	one or more
Gathering knowledge and exchanging best practices on measures reducing underage drinking and heavy episodic drinking	1.200.000	2.1.1.2	one or more
Gathering knowledge and exchanging best practises to on measures to prevent illicit drug use in line with the minimum quality standards in drug demand reduction	600.000	2.1.1.3	one or more
Support to Member States and stakeholders to address the chronic disease challenge	2.500.000	2.1.1.4	one or more
Donor selection and protection	550.000	2.1.4.3	one or more



## Come partecipare?

Vi interessa partecipare al programma per la salute?

Tutte le **informazioni, insieme al modulo di candidatura**, sono disponibili qui:

**Agenzia Esecutiva per i Consumatori, Salute, Agricoltura e Alimentazione - CHAFEA**

## Il referente nel nostro paese

Contattate il referente nel vostro paese per ottenere assistenza e consigli:

### **Punto focale nazionale**

Dr **Giovanni NICOLETTI**

Ministero della Salute

[nfp\\_eahc@sanita.it](mailto:nfp_eahc@sanita.it)



**Per ulteriori informazioni:**

<http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/hp/>





## Active & Healthy Ageing

*A European Innovation  
Partnership*





# European Innovation Partnership on Active & Healthy Ageing



crosscutting, connecting & engaging **stakeholders** across sectors, from private & public sector

**+2 HLY by 2020**  
*Triple win for Europe*



## Action Groups

-  Improving prescriptions and adherence to treatment
-  Better management of health: preventing falls
-  Preventing functional decline & frailty
-  Integrated care for chronic conditions, inc. telecare
-  ICT solutions for independent living & active ageing
-  Age-friendly cities and environments



I settori d'intervento prioritari sono stati individuati nel [piano strategico di attuazione](#) e nel [piano operativo](#), adottati nel 2011 dal [gruppo direttivo](#) incaricato dell'avvio e dell'attuazione della partnership.

Per realizzare il piano tutti i soggetti interessati hanno iniziato a collaborare nell'ambito di [gruppi d'azione](#).

- ✓ [Action Group A1: \*\*Prescription and adherence\*\* action at regional level.](#)
- ✓ [Action Group A2: Personalized health management: \*\*Falls prevention\*\*.](#)
- ✓ [Action Group A3: Prevention of functional \*\*decline and frailty\*\*.](#)
- ✓ [Action Group B3: \*\*Integrated care for chronic diseases\*\*, including remote monitoring at regional level.](#)
- ✓ [Action Group C2: Interoperable independent \*\*living solutions\*\*.](#)
- ✓ [Action Group D4: Age \*\*friendly buildings, cities and environments\*\*.](#)

Stakeholders wishing to get involved in the advancing of Specific Actions have formed **Action Groups** through the "[Invitation for Commitment](#)" application process.

In each Action Group, stakeholders *commit to running a number of activities, contributing towards the headline target, starting with the creation and implementation of an Action Plan.*

E' attivo online anche un "**Marketplace per idee innovative**", che rientra in EIP.

*E' uno spazio interattivo per scambiare opinioni, trovare partners o iniziative al fine di mettere in pratica delle idee innovative:*

<https://webgate.ec.europa.eu/eipaha/>



**Per ulteriori Informazioni:**

[http://ec.europa.eu/research/innovation-union/index\\_en.cfm?section=active-healthy-ageing](http://ec.europa.eu/research/innovation-union/index_en.cfm?section=active-healthy-ageing)

## ERA-Nets finanziate in Horizon 2020 con partecipazione italiana



<b>E-Rare-3</b>	ERA-NET <b>rare disease</b> research implementing IRDiRC objectives	AGENCE NATIONALE DE LA RECHERCHE	FR
<b>ERACoSysMed</b>	ERACoSysMed - Collaboration on <b>systems medicine</b> funding to promote the implementation of systems biology approaches in clinical research and medical practice	FORSCHUNGSZENTRUM JUELICH GMBH	DE
<b>JPco-fuND</b>	ERA-NET for establishing synergies between the Joint Programming on <b>Neurodegenerative Diseases</b> Research and Horizon 2020	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)	FR
<b>TRANSCAN-2</b>	ERA-NET: Aligning national/regional translational <b>cancer research</b> programmes and activities	MINISTERO DELLA SALUTE	IT
<b>ERA-CVD</b>	ERA-NET on <b>cardiovascular diseases</b> to implement joint transnational research projects and set up international cooperations	DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV	DE
<b>JPI-EC-AMR</b>	ERA-NET for establishing synergies between the Joint Programming Initiative on <b>Antimicrobial Resistance</b> Research and Horizon 2020	VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL	SE
<b>NEURON Cofund</b>	ERA NET NEURON in the area of <b>brain-related diseases and disorders of the nervous system</b>	DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV	DE

## Comlessivo SC1 Bandi 2014-2015-2016

No. topics	Budget Mill. EUR	Proposte presentate 	Proposte finanziate 	Tasso di successo 
72	1.438,7	2.806	257	9,15%

### Partecipazione



No. Partecipanti italiani in proposte presentate	No. Partecipanti italiani finanziati	Tasso di successo partecipanti Italiani
3.061	274	8,9%

### Coordinamento



No. Proposte presentate a coordinamento italiano	No. Coordinamenti italiani finanziati	Tasso di successo coordinatori Italiani
375 (13,3% del totale EU)	18	4,8%

# Proseguiamo ...

**APRE**  
**Agenzia per la Promozione della Ricerca Europea**  
via Cavour, 71  
00184 - Roma  
[www.apre.it](http://www.apre.it)  
Tel. (+39) 06-48939993  
Fax. (+39) 06-48902550

## Health NCP